|Articles|October 24, 2022
How CDMOs Can Support Nanoparticles for Gene Therapy, Immuno-Oncology, and Vaccines
Author(s)Emergent CDMO
Many CDMOs outsource their nanoparticle supply chain, but in house manufacturing of nanoparticles at CDMOs is anticipated to create new market opportunities.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
A-TEEM: A Novel, Powerful Tool for Evaluating and Monitoring Cell Culture Media
2
Challenges, Innovations, and Future Outlook of Biologics Formulations
3
CPHI Frankfurt 2025 Highlights Global Pharma Innovation and Manufacturing Leadership
4
Behind the Headlines Episode 27: Unpacking Mega Deals and R&D Directions
5
